Weekly recap highlights Axsome Q2 revenue jump and PDUFA timeline
Axsome Therapeutics reported Q2 revenue of $218.4M, driven by AUVELITY, with strong Medicare 65+ sales and seven ongoing trials. The recap also notes an upcoming FDA PDUFA and Phase 3 readouts; Piper Sandler reiterated overweight with a $258 target.